STOCK TITAN
  1. Home
  2. News
  3. NDRA

ENDRA Life Sciences Inc - NDRA STOCK NEWS

Welcome to our dedicated news page for ENDRA Life Sciences (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ENDRA Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ENDRA Life Sciences's position in the market.

News
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) reports financial results for Q4 2023, including installing the first TAEUS system in the UK for clinical evaluation. FDA's review of ENDRA's De Novo request is ongoing. The company showcased the TAEUS system at key medical conferences, expanded its intellectual property portfolio, and obtained a new ICD-10-CM code for improved NAFLD diagnostics. Financially, operating expenses decreased, leading to a lower net loss compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.52%
Tags
earnings
-
News
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) will report financial results for Q4 and full year 2023 on March 28, 2024. The company will host a conference call to discuss results, corporate updates, and answer questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.76%
Tags
conferences earnings
-
News
ENDRA Life Sciences Installs First TAEUS System in the UK
Rhea-AI Summary
ENDRA Life Sciences Inc. installs TAEUS liver system at King's College Hospital in London for a clinical study comparing liver fat assessment accuracy with MRI. The study aims to include 75 subjects and publish findings in a medical journal. The partnership with KCH highlights ENDRA's commitment to healthcare delivery and potential expansion into the UK NHS network.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
News
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System
Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) welcomes the adoption of the ICD-10 K76.0 code for Non-Alcoholic Fatty Liver Disease (NAFLD) diagnosis, signaling advancements in liver health. The update facilitates standardized billing, promoting innovative diagnostic technologies like ENDRA's TAEUS system. The pharmaceutical industry and medical associations are focusing on liver disease, with increased screening guidelines. ENDRA aims to lead in liver health diagnostics with a global patent portfolio and commitment to research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
News
ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe
Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) expands its intellectual property portfolio with the issuance of three new patents in the U.S., China, and Europe, bringing the total to 74 worldwide. These patents protect the TAEUS system, enhancing radiofrequency energy absorption, reducing signal noise, and enabling precise temperature monitoring during surgical procedures and thermal ablation. The innovative technology aims to optimize treatment parameters, minimize damage to healthy tissue, and effectively target cancerous cells for improved therapeutic outcomes with reduced side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
News
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology
Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) has announced the issuance of a new patent, U.S. Patent No. 11828727, titled 'Thermoacoustic Probe.' This patent further strengthens the company's Intellectual Property (IP) portfolio, bringing the total number of globally issued patents to 71. The '727 patent focuses on a thermoacoustic probe design with an optical transducer and an integrated wedge, enhancing the technology's ability to minimize unwanted signals and optimize radiofrequency signals to targeted regions of interest. ENDRA's Chairman and CEO, Francois Michelon, expressed satisfaction with the company's IP momentum and highlighted the significance of this patent in addressing high unmet clinical needs, especially as the TAEUS technology advances through regulatory review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
News
ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference
Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) to participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
News
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) reports Q3 2023 financial results and business update, including positive TAEUS clinical data, showcased TAEUS system at major clinical conferences, achieved an intellectual property milestone, and De Novo request advanced to next stage of review at FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
earnings
-
News
ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announces the issuance of three new patents, including one in the U.S. and two in China, bringing their intellectual property portfolio to 70 issued patents worldwide. The patents enhance the IP protection for the novel TAEUS® system, focusing on thermoacoustic probe, transducer with integrated switch, and acoustically isolated thermoacoustic imaging probe. Francois Michelon, ENDRA's Chairman and CEO, emphasizes the significance of these patents in addressing unmet clinical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
News
ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023
Rhea-AI Summary
ENDRA Life Sciences Inc. (NDRA) to Report Q3 2023 Financial Results on November 14, 2023, After Market Close
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
conferences earnings
Stock NDRA logo
ENDRA Life Sciences Inc

Nasdaq:NDRA

NDRA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NDRA Stock Data

4.08M
10.68M
3.15%
1.19%
0.28%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States
Ann Arbor

About NDRA

endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.